Serum CXCL12 Levels as a Novel Predictor of Future Stroke Recurrence in Patients with Acute Ischemic Stroke

Molecular Neurobiology

Volumn 53, Issue 5, 2016, Pages 2807-2814

  Gu, Xiao Lin ^a   Liu, Lin ^a   Lu, Xiang Dong ^a   Liu, Zhen Rui ^a  

^a Department of Emergency The People s Hospital of Laiwu City   (China)

Author keywords

Acute ischemic stroke; CXC chemokine ligand 12; Predictor; Recurrence

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; STROMAL CELL DERIVED FACTOR 1; TRIACYLGLYCEROL; CXCL12 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PREDICTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECURRENCE RISK; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; COMPLICATION; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; STATISTICAL MODEL;

AGED; BRAIN ISCHEMIA; CHEMOKINE CXCL12; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; ROC CURVE; STROKE;

EID: 84926219755     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9151-0     Document Type: Article

References (25)

1. Zhang ZG, Wang C, Wang J et al (2015) Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke. Mol Neurobiol 51(1):230–239
2. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F (2004) The global stroke initiative. Lancet Neurol 3:391–393
3. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312–318
4. Li S, Gao Y, Ma W et al (2014) The relationship between serum lipoprotein (a) levels and ischemic stroke risk: a cohort study in the Chinese population. Inflammation 37:686–693
5. Wu MH, Song FY, Wei LP et al (2014) Serum levels of thioredoxin are associated with stroke risk, severity, and lesion volumes. Mol Neurobiol. doi:10.1007/s12035-014-9016-y
6. Ballantyne CM, Hoogeveen RC, Bang H et al (2005) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165:2479–2484
7. Dong X, Chang G, Ji XF et al (2014) The relationship between serum insulin-like growth factor I levels and ischemic stroke risk. PLoS One 9:e94845
8. Wang C, Gao L, Zhang ZG et al (2015) Procalcitonin is a stronger predictor of long-term functional outcome and mortality than high-sensitivity C-reactive protein in patients with ischemic stroke. Mol Neurobiol. doi:10.1007/s12035-015-9112-7
9. Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2:108–115
10. Takahashi M (2010) Role of the SDF-1/CXCR4 system in myocardial infarction. Circ J 74:418–423
11. Kim YS, Baek W, Kim MK et al (2012) Association between serum stromal cell-derived factor-1α and long-term outcome of acute ischemic stroke. Eur Neurol 67:363–369
12. Bogoslovsky T, Spatz M, Chaudhry A, Maric D, Luby M, Frank J et al (2011) Stromal-derived factor-1α correlates with circulating endothelial progenitor cells and with acute lesion volume in stroke patients. Stroke 42:618–625
13. Paczkowska E, Kucia M, Koziarska D, Halasa M, Safranow K, Masiuk M et al (2009) Clinical evidence that very small embryonic-like stem cells are mobilized into peripheral blood in patients after stroke. Stroke 40:1237–1244
14. Schutt RC, Burdick MD, Strieter RM et al (2012) Serum CXCL12 levels as a predictor of future stroke. Stroke 43:3382–3386
15. Hatano S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54:541–553
16. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsanl WG et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870
17. Adams HP Jr, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
18. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521–1526
19. Sims JR, Gharai LR, Schaefer PW, Vangel M, Rosenthal ES (2009) ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology 72:2104–2110
20. Wurster T, Stellos K, Geisler T, Seizer P, Andia ME, Schuster A et al (2012) Expression of stromal-cell-derived factor-1 (SDF-1): a predictor of ischaemic stroke? Eur J Neurol 19:395–401
21. Li M, Ransohoff RM (2008) Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol 84:116–131
22. Wang Y, Huang J, Li Y et al (2012) Roles of chemokine CXCL12 and its receptors in ischemic stroke. Curr Drug Targets 13:166–172
23. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD (2000) The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 86:131–138
24. Hill WD, Hess DC, Martin-Studdard A et al (2004) SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol 63:84–96
25. Schönemeier B, Schulz S, Hoellt V et al (2008) Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. J Neuroimmunol 198:39–45